A Phase 3 Randomized Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CA209-76K)

Brief description of study

The purpose of this research study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab in subjects with early stage (IIB/C) melanoma (a type of skin cancer) that have had their tumors completely removed, but could possibly have their cancer return.


Clinical Study Identifier: s19-01045
ClinicalTrials.gov Identifier: NCT04099251
Principal Investigator: Jeffrey S. Weber.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.